Coverage more than doubled from 17% in 2024. Health Canada has cleared three generic semaglutide products, and Lockton urges plans to rework design to capture savings.
Recap by typeshit. Full story at Benefits and Pensions Monitor.
Business Day says medicines endorsed by the WHO still aren't available to public sector patients. The drugs involved aren't named in the share.
A study of 288,907 insured people found other medical costs rose about 22 cents per drug dollar. Also covers Medicare's $245 Bridge price and employer cutbacks.
ASU's Justin Bina told the New York Post that people starting GLP-1 drugs become willing to pay more per pound for certain proteins, even as cattle stocks hit a 75-year low.
Zacks expects $10.1 billion from Mounjaro and $5.1 billion from Zepbound, and notes Lilly plans to seek retatrutide approval in early 2027.
Mayo's GI team highlights Atieh's feature, which looks past the scale to gains like better HbA1c and lipid profiles.
Ott covered emerging vaccine-style approaches using peptides, DNA and mRNA at a special symposium on melanoma.
Loading…